Business Wire (Mon, 12-Jan 8:05 AM ET)
Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Business Wire (Wed, 7-Jan 8:05 AM ET)
Globe Newswire (Tue, 16-Dec 6:30 AM ET)
Business Wire (Mon, 8-Dec 8:05 AM ET)
Business Wire (Tue, 2-Dec 8:05 AM ET)
Business Wire (Mon, 24-Nov 8:05 AM ET)
Business Wire (Wed, 19-Nov 8:05 AM ET)
Harmony Biosciences to Participate in Upcoming Investor Conferences
Business Wire (Tue, 18-Nov 8:05 AM ET)
HRMY Lifts Revenue Guidance After Record Q3 WAKIX Growth and Highest-Ever Patient Gains
Market Chameleon (Thu, 23-Oct 7:14 AM ET)
Market Chameleon (Wed, 24-Sep 4:43 AM ET)
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Harmony Biosciences Hldgs trades on the NASDAQ stock market under the symbol HRMY.
As of February 9, 2026, HRMY stock price declined to $37.08 with 338,746 million shares trading.
HRMY has a beta of 1.00, meaning it tends to be less sensitive to market movements. HRMY has a correlation of 0.14 to the broad based SPY ETF.
HRMY has a market cap of $2.14 billion. This is considered a Mid Cap stock.
Last quarter Harmony Biosciences Hldgs reported $239 million in Revenue and $1.08 earnings per share. This beat revenue expectation by $14 million and exceeded earnings estimates by $.20.
In the last 3 years, HRMY traded as high as $50.75 and as low as $18.61.
The top ETF exchange traded funds that HRMY belongs to (by Net Assets): CALF, USVM, SFLO, FYX, ECML.
HRMY has underperformed the market in the last year with a return of -4.4%, while SPY returned +15.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in HRMY shares. However, HRMY has outperformed the market in the last 3 month and 2 week periods, returning +19.8% and +0.7%, while SPY returned +3.8% and +0.7%, respectively. This indicates HRMY has been having a stronger performance recently.
HRMY support price is $36.36 and resistance is $38.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HRMY shares will trade within this expected range on the day.
